Equities

SkinBioTherapeutics PLC

SkinBioTherapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)14.00
  • Today's Change0.00 / 0.00%
  • Shares traded727.72k
  • 1 Year change-37.78%
  • Beta2.5509
Data delayed at least 20 minutes, as of Nov 13 2024 12:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis.

  • Revenue in GBP (TTM)161.65k
  • Net income in GBP-2.88m
  • Incorporated2015
  • Employees11.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SBTX:LSE since
announced
Transaction
value
Bio-Tech Solutions LtdAnnounced11 Oct 202411 Oct 2024Announced24.44%1.63m
Dermatonics LtdDeal completed25 Jan 202425 Jan 2024Deal completed-5.08%3.73m
Data delayed at least 20 minutes, as of Nov 13 2024 12:31 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImmuPharma PLC-69.96k-2.46m6.90m5.00--2.56-----0.0065-0.0065-0.00020.0065-0.019-----13,992.00-66.99-86.13-111.20-106.39-------8,634.98---7.270.00------23.26------
LungLife AI Inc22.75k-3.50m7.27m15.00--0.3514--319.72-0.1317-0.13170.00080.24420.0027--2.901,516.70-42.18---47.78--100.00---15,403.45------0.0259--91.67--28.83------
Cizzle Biotechnology Holdings PLC0.00-2.70m7.53m67.00--9.49-----0.0073-0.00730.000.0020.00-------146.70-144.15-157.81-167.75-----------0.450.00-------88.27------
IXICO PLC6.00m-1.87m8.11m89.00--0.4215--1.35-0.0386-0.03860.12410.20760.4725--3.5467,415.73-14.694.35-16.585.3346.9062.09-31.106.61----0.03120.00-22.894.32-214.15--92.12--
Synairgen plc0.00-6.92m8.63m36.00--0.8972-----0.0344-0.03440.000.04750.00----0.00-47.18-54.01-54.24-60.02------------0.00------52.35---26.64--
OptiBiotix Health PLC569.00k-2.98m12.24m5.00--1.66--21.52-0.0317-0.03170.00610.07520.06341.351.07113,800.00-33.2516.82-34.8517.5247.9853.03-524.43183.495.36-2.030.00100.1440.924.60-178.82------
Hemogenyx Pharmaceuticals PLC0.00-5.18m14.89m17.00--4.86-----0.0042-0.00420.000.00230.00----0.00-77.79-82.19-85.95-95.97-----------19.940.4794-------68.14--36.68--
Incanthera PLC0.00-1.55m18.70m7.00---------0.0189-0.01890.00-0.00610.00----0.00-852.34-115.31---153.87---------------------12.76------
Shield Therapeutics PLC20.88m-36.17m20.72m73.00--38.31--0.9924-0.0477-0.04770.02740.00070.47234.061.69286,068.50-81.80-56.68-136.41-67.4434.6552.20-173.18-365.890.8968-15.290.9736--137.951.9533.13---2.50--
Arecor Therapeutics PLC4.90m-8.67m28.70m50.00--4.58--5.86-0.283-0.2830.160.16580.3213--1.6797,980.00-56.84---89.06-------176.89--1.27--0.0523--90.30--7.62------
Sareum Holdings Plc0.00-3.42m31.50m5.00--12.89-----0.0422-0.04220.000.01960.00-------142.89-81.13-209.37-96.44-------23,877.73---163.36---------7.14------
Skinbiotherapeutics PLC161.65k-2.88m31.98m11.00--7.30--197.84-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Poolbeg Pharma PLC0.00-4.38m42.00m8.00--3.37-----0.0088-0.00880.000.02490.00----0.00-29.11---30.18--------------0.00------16.11------
Data as of Nov 13 2024. Currency figures normalised to SkinBioTherapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

10.14%Per cent of shares held by top holders
HolderShares% Held
Yarra Investment Management Ltd.as of 30 Nov 202313.82m6.05%
Unicorn Asset Management Ltd.as of 08 Apr 20247.89m3.46%
Evelyn Partners Investment Management LLPas of 31 Dec 20231.46m0.64%
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.